Share on StockTwits
 

Stock Analysts’ ratings reiterations for Monday, February 24th:

Agrium (NYSE:AGU) had its neutral rating reiterated by analysts at Zacks. The firm currently has a $95.00 price target on the stock.

Ashtead Group plc (LON:AHT) had its buy rating reissued by analysts at Cantor Fitzgerald Europe. They currently have a GBX 960 ($15.97) price target on the stock.

Ashtead Group plc (LON:AHT) had its buy rating reiterated by analysts at Cantor Fitzgerald Europe. They currently have a GBX 960 ($15.97) price target on the stock.

American Axle & Manufacturing Holdings (NYSE:AXL) had its neutral rating reaffirmed by analysts at Zacks. The firm currently has a $21.00 target price on the stock. Zacks’ analyst wrote, “American Axle reported fourth-quarter 2013 adjusted earnings of $0.70 per share, surpassing the Zacks Consensus Estimate of $0.51. Earnings per share rebounded from a loss of $0.02 in the comparable quarter of 2012. Revenues went up 12.8% to $831.3 million, missing the Zacks Consensus Estimate of $872 million. American Axle expects an increase in sales to $3.75-$3.8 billion in 2014. The company should benefit from the new and incremental businesses to be launched, increased manufacturing in low cost countries, efforts to diversify customer base and the rising cash balance. However, rising debt and pricing pressure by original equipment manufacturers (OEMs) remain causes for concern. Therefore, we maintain a Neutral recommendation on the stock.”

Carillion (LON:CLLN) had its hold rating reaffirmed by analysts at Cantor Fitzgerald Europe. They currently have a GBX 350 ($5.82) target price on the stock.

Carillion (LON:CLLN) had its hold rating reissued by analysts at Cantor Fitzgerald Europe. Cantor Fitzgerald Europe currently has a GBX 350 ($5.82) target price on the stock.

Ecolab (NYSE:ECL) had its neutral rating reissued by analysts at Zacks. The firm currently has a $107.00 price target on the stock. Zacks’ analyst wrote, “Ecolab’s 2013-fourth quarter adjusted EPS of $1.04 grew 17% but lagged the Zacks Consensus Estimate by a penny. Year-over-year growth was led by solid top-line growth, cost efficiency programs and synergies. Revenues grew 16.9% to $3,559.5 million and topped the mark. Global Energy and Global Specialty businesses posted strong results in the quarter. Ecolab is active on the acquisition front and continues to explore opportunities to expand in emerging markets to sustain growth. However, currency fluctuations, higher raw material prices and stiff competition remain significant headwinds. As a result, we reiterate our Neutral recommendation on Ecolab and set a target of $107.00.”

easyJet plc (LON:EZJ) had its hold rating reissued by analysts at Cantor Fitzgerald Europe. They currently have a GBX 1,400 ($23.28) price target on the stock.

easyJet plc (LON:EZJ) had its hold rating reissued by analysts at Cantor Fitzgerald Europe. The firm currently has a GBX 1,400 ($23.28) target price on the stock.

HSBC Holdings plc (LON:HSBA) had its buy rating reissued by analysts at Investec. The firm currently has a GBX 745 ($12.39) price target on the stock.

Intertek Group (LON:ITRK) had its hold rating reissued by analysts at Cantor Fitzgerald Europe. Cantor Fitzgerald Europe currently has a GBX 3,065 ($50.97) target price on the stock.

Intertek Group (LON:ITRK) had its hold rating reaffirmed by analysts at Cantor Fitzgerald Europe. They currently have a GBX 3,065 ($50.97) target price on the stock.

Allscripts Healthcare Solutions (NASDAQ:MDRX) had its neutral rating reissued by analysts at Zacks. They currently have a $19.00 target price on the stock. Zacks’ analyst wrote, “Allscripts Healthcare Solutions’ earnings of $0.04 for the 2013-fourth quarter plunged 55.6% and met the Zacks Consensus Estimate. However, revenues of $351.0 million surpassed the mark despite being flat year-over-year. Despite the soft results, bookings improved significantly in the quarter driven by new upgraded products. The company’s continues to benefit from the movement among medical providers seeking to comply with federal EHR requirements. Further, its non-EHR offerings for the untapped HCIT market, such as population health management and care coordination are considered to be future growth drivers. However, Allscripts’ ability to integrate acquisitions remains to be proven and it continues to face strong competition in a fragmented market. Hence, we reaffirm our Neutral recommendation with a target of $19.00.”

Newalta (TSE:NAL) had its buy rating reiterated by analysts at Mackie.

Pharmacyclics (NASDAQ:PCYC) had its neutral rating reissued by analysts at Zacks. The firm currently has a $159.00 price target on the stock. Zacks’ analyst wrote, “Pharmacyclics’ fourth quarter 2013 earnings of $0.82 per share beat the Zacks Consensus Estimate of $0.77 per share. Moreover, earnings in the final quarter of 2013 were 46% above the year-ago figure. The year-over-year increase in earnings was primarily due to higher revenues. The massive increase was primarily attributable to a 90% jump in collaboration and license agreement revenue to $110 million. Revenues in the final quarter of 2013 were also boosted by the Nov 2013 U.S. approval of Imbruvica for MCL. The drug recorded sales of $13.6 million in the final quarter of 2013. The approval for the more lucrative CLL indication in Feb 2014 is a major positive for Pharmacyclics. We maintain our Neutral recommendation on the stock.”

SCANA Corp. (NYSE:SCG) had its neutral rating reiterated by analysts at Zacks. They currently have a $52.00 price target on the stock. Zacks’ analyst wrote, “SCANA Corporation reported weak fourth-quarter earnings that missed the Zacks Consensus Estimate. Going forward, we expect modest growth to continue thanks to the utility’s improving electric margins and rate increases. We are also bullish about the steady progress of new electric generation plants and nuclear expansion projects. The company is a stable, relatively strong and regulated electric utility, supported by regional demographics and a favorable electric utility rate. However, we remain on the sidelines considering the company’s sensitivity to changes in coal, gas, oil and other commodity prices. Construction costs and delays could impact the timing of rate base growth, earnings, cash flow and the quality of the balance sheet. Considering this, we expect the stock to perform on par with the broader industry. “

Serco Group plc (LON:SRP) had its sell rating reaffirmed by analysts at Cantor Fitzgerald Europe. They currently have a GBX 365 ($6.07) target price on the stock.

Serco Group plc (LON:SRP) had its sell rating reiterated by analysts at Cantor Fitzgerald Europe. They currently have a GBX 365 ($6.07) target price on the stock.

SunTrust (NYSE:STI) had its neutral rating reaffirmed by analysts at Zacks. They currently have a $39.00 price target on the stock. Zacks’ analyst wrote, “SunTrust’s fourth-quarter 2013 earnings were well ahead of the Zacks Consensus Estimate. Results benefited from decline in both provision for credit losses and operating expenses. These were partially offset by a decrease in revenue. Further, credit quality improved in the quarter while capital ratios were a mixed bag. We believe that strong credit quality and a favorable deposit mix will continue to remain driving forces at SunTrust. Moreover, the company’s cost-cutting initiatives are commendable amid the sluggish economic recovery and overall industry challenges. Nevertheless, we remain concerned about the company’s exposure to risky assets and continued regulatory pressures.”

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.